March 19, 2009
Enzon Treats Patients with Survivin Antagonist
-- Enzon's compound advances into the clinic for patients with solid tumors and lymphomas--

March 16, 2009
Enzon to Present at 29th Annual Cowen and Company Conference

February 13, 2009
Enzon to Release Fourth Quarter 2008 Earnings on Thursday, February 19, 2009; Conference Call and Webcast to Follow

February 10, 2009
Enzon Discontinues Further Development of rhMBL

February 10, 2009
Enzon Announces IND Acceptance for its Survivin Antagonist
-- Phase I study to open for patients with solid tumors--

February 04, 2009
Enzon to Present at 11th Annual BIO CEO & Investor Conference

January 28, 2009
Enzon Nominates Two New Candidates for its Board of Directors

January 21, 2009
Enzon Concludes Tender Offer for a Portion of Its Debt

January 08, 2009
Enzon Pharmaceuticals Extends Tender Offer for a Portion of its Debt

December 08, 2008
Enzon Pharmaceuticals Commences Tender Offer For a Portion of its Debt

December 03, 2008
Enzon to Purchase a Portion of its Outstanding Debt

December 01, 2008
Enzon Discontinues its Plan to Spin-off its Biotechnology Business

November 05, 2008
Enzon Reports Solid Third Quarter 2008 Results
-- Provides update on the sale of the specialty pharma business --

October 29, 2008
Enzon to Release Third Quarter 2008 Earnings on Wednesday, November 5, 2008; Conference Call and Webcast to Follow

October 27, 2008
Enzon's HIF-1 alpha Antagonist Shows Antitumor Activity
--Innovative and diverse pipeline advances--

October 20, 2008
Enzon Presents New Data on its LNA Programs
--Platform shows promise--

October 16, 2008
Enzon To Present Data at EORTC-NCI-AACR
--New clinical data and LNA cancer target revealed--

September 30, 2008
Enzon's New Oncaspar-IV™ Receives Orphan Drug Status in the EU
-- Improved version to expand global potential --

August 11, 2008
Enzon Pharmaceuticals Announces Intention to Explore Strategic Alternatives for Specialty Pharmaceuticals Business
-- Enzon Continues to Pursue Plan to Spin-off Biotechnology Business --

August 06, 2008
Enzon Reports Solid Second Quarter 2008 Results
-- Product revenues increase 17% --

July 31, 2008
Enzon Files For Spin-Off of Biotech Business

July 29, 2008
Enzon to Release Second Quarter 2008 Earnings on Wednesday, August 6, 2008; Conference Call and Webcast to Follow

July 02, 2008
Enzon Eliminates its Remaining 2008 Debt

May 28, 2008
Jack Geltosky, Ph.D. Joins Enzon's Board of Directors

May 22, 2008
Enzon Stockholders Approve Company Proposals at 2008 Annual Meeting

May 20, 2008
Enzon Announces Clinical Data From PEG-SN38 and rhMBL Studies at ASCO -- Company will host reception --

May 07, 2008
Enzon Pharmaceuticals, Inc. Announces Plan To Spin-Off Biotechnology Business

April 30, 2008
Enzon to Release First Quarter 2008 Earnings on Wednesday, May 7, 2008; Conference Call and Webcast to Follow

April 23, 2008
Cimzia®, Utilizing Enzon's PEGylation Technology, Approved in the U.S.

April 09, 2008
Enzon Pharmaceuticals to Add New Independent Director to Board

March 17, 2008
Enzon's PEG-SN38 Featured in Clinical Cancer Research

February 14, 2008
Enzon Reports Significant Progress on the Reduction of Its Debt

February 12, 2008
Enzon Pharmaceuticals to Add New Independent Director to Board

November 29, 2007
Enzon to Present at BMO Capital Markets Focus on Healthcare Conference

October 30, 2007
Enzon Reports Third Quarter 2007 Results

October 30, 2007
Enzon Initiates Second Phase 1 Study of Its HIF-1 Alpha Antagonist